![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
STP7 (Mavoglurant) is the most clinically advanced negative allosteric modulator of the glutamate receptor 5 (mGluR5 NAM). It is being evaluated for the treatment of cocaine use disorder.
Lead Product(s): Mavoglurant
Therapeutic Area: Psychiatry/Psychology Product Name: STP7
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 02, 2024
Details:
The agreement covers the clinical development program of STP7 (mavoglurant) to treat patients diagnosed with cocaine use disorder (CUD), including a Phase 3 study.
Lead Product(s): Mavoglurant
Therapeutic Area: Psychiatry/Psychology Product Name: STP7
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: National Institute on Drug Abuse
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 08, 2023
Details:
Under the terms of the agreement, STALICLA has acquired worldwide rights to AFQ056 (mavoglurant) for substance-use disorders, neurodevelopmental disorders, and other indications. Mavoglurant is a selective non allosteric metabotropic glutamate receptor 5 (mGluR5) antagonist.
Lead Product(s): Mavoglurant
Therapeutic Area: Psychiatry/Psychology Product Name: AFQ056
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Novartis Pharmaceuticals Corporation
Deal Size: $270.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 09, 2023